1 / 84

The Child With a Malignancy

The Child With a Malignancy. Jan Bazner-Chandler CPNP,MSN, CNS, RN. Developmental and Biologic Variances. Most childhood cancers arise for embryonic mesodermal germ layer Involves tissues of: CNS, bone, muscle, endothelial tissue, connective tissue, blood, lymph tissue

alta
Download Presentation

The Child With a Malignancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Child With a Malignancy Jan Bazner-Chandler CPNP,MSN, CNS, RN

  2. Developmental and Biologic Variances • Most childhood cancers arise for embryonic mesodermal germ layer • Involves tissues of: CNS, bone, muscle, endothelial tissue, connective tissue, blood, lymph tissue • Grows in a short period of time • 80% have metastasis at time of diagnosis

  3. Assessment • Unusual mass or swelling • Unexplained paleness and loss of energy • Spontaneous bruising • Prolonged, unexplained fever • Headaches in morning • Sudden eye or vision changes • Excessive – rapid weight loss

  4. Diagnostic Tests • X-ray • Skeletal survey • CT scan • Ultrasound • MRI • Bone marrow aspiration • CBC with absolute neutrophil count • Urinalysis • Lumbar puncture • Urine catecholamines

  5. Treatment Modalities • Determined by: • Type of cancer • Location • Extent of disease

  6. Surgical Management • The oldest form of cancer treatment • Surgery plays important role in initial diagnosis: biopsy of primary tumor. • Excision of tumor when possible • Facilitating treatment: insertion of catheters for long-term treatment

  7. Radiation Therapy • The use of ionizing radiation to break apart bonds within a cell causing cell damage and death. • External beam therapy accounts for the majority of radiation treatments in children. • Problems: radiation beams cannot distinguish between malignant cells and healthy cells.

  8. Chemotherapy • Primary treatment modality used to cure many pediatric cancers. • Chemotherapy is the use of drugs to destroy cancer cells. • The destruction is accomplished by inhibiting cells within the body to divide, which eventually leads to cell death.

  9. Chemotherapy • Can be given in addition to another form of therapy such as radiation or surgery. • Drugs may be administered before surgery to reduce size of tumor. • Adjuvant chemotherapy is used after surgery or radiation therapy to prevent relapse.

  10. Chemotherapy • Combination chemotherapy is the use of more than one class of drug. • Administering different classes of chemo drugs ensures a greater chance of achieving complete cancer cell destruction and achieving remission.

  11. Administration • Chemotherapy can be given by mouth, subcutaneous or intramuscular injections, intravenously, or intrathecally. • Oral route used if drug is well absorbed and non irritating to the GI tract • Sub-q or IM: Slow systemic release • IV push, piggyback or intravenous infusion

  12. Goals of Chemotherapy • Reducing the primary tumor size • Destroying cancer cells • Preventing metastases and microscopic spread of the disease

  13. Chemotherapy Drugs • Alkylating drug: attack DNA • Antimetabolites: interfere with DNA production • Antitumor antibiotics: interferes with DNA production • Plant alkaloids: prevent cells from dividing • Steroid hormones: slow growth of some cancers

  14. Bone Marrow Transplant • HSCT: Hematopoietic Stem Cell Transplant: CHLA has one of the largest program. • The option of HSCT depends on the patients disease, disease status, and general physical condition. • Involves: • Umbilical cord blood • Parent’s stem cells

  15. Gene Therapy • Use of gene therapy in the treatment of childhood cancer is promising yet complex and still in early phases of clinical application.

  16. Management • Patient / family education • Begins at time of diagnosis • Continues through treatment phases • Maintained in post-survival years • Support if death of child

  17. Pain Management • Pain caused by disease • Pain with procedures and treatments • Pain associated with side effects of treatment

  18. Pain Management • Pharmacologic • Non-Pharmacologic • Sedation or anesthetic medications • EMLA cream • Conscious sedation

  19. Pain Control

  20. Immunosuppression and Infection • Children with cancer become immune impaired from a number of causes: • Lymphocyte production is altered • Splenic dysfunction can prevent maturation of blood cells and alteration is inflammatory response. • Cancer therapy can decrease immunoglobulin concentrations.

  21. Neutropenia • Significant neutropenia can develop during chemotherapy creating an increased risk of infection in the child with cancer. • Neutropenia occurs when the absolute neutrophil count decreases below 500.

  22. Treatment for Neutropenia • Granulocyte colony stimulating factor decreases the duration of neutropenia by stimulating the proliferation of the progenitor cells of the granulocytes, specifically the neutophils. • G-CSF: 5mcg/kg/day given subcutaneous

  23. Varicella • If an immunosuppressed child with no history of varicella infection or varicella immunization has direct contact with an individual with chickenpox or shingles, varicella zoster immune globulin should be administered. • Acyclovir IV is used in some cases.

  24. Varicella Immunizations • Three months after chemotherapy • Off prednisone • Many will have already had the immunization as a toddler since it is now a required immunization.

  25. Central Venous Access Devices • Two decades ago, CVAD were introduced as an integral part of the pediatric oncology patient’s treatment plan. • Used to deliver chemotherapy, blood components, antibiotics, fluids, TPN, medications and blood sampling.

  26. CVAD Infection Prevention • Teach family to report signs of catheter infections: fever, chills, swelling, pain, drainage, or erythema. • Aseptic technique for dressing changes and heparin flushing. • Avoid trauma to device • Observe for catheter occlusion

  27. Chemotherapy Side Effect • Drugs affect not only the cancer cells but also healthy cells. • Cells most affected are rapidly growing cells such as hair follicles, reproductive system, bone marrow and gastrointestinal tract.

  28. Management of Side Effects

  29. Malnutrition • Occurs in 8 to 32% of the pediatric oncology population • Nutritional goals focus on maintaining normal growth and development as well as preventing nutritional deficiencies.

  30. Nutrition Interventions • Initial nutritional assessment • History of child’s eating habits, food allergies, use of nutritional supplements, base line weight and height measurements. • Enteral feedings at night: preserve intestinal mucosa by keeping it functional

  31. Nausea and Vomiting • Most common side effect of cancer treatment. • Chemotherapy-associated vomiting is a reflex controlled by chemoreceptor trigger zone that stimulates the vomiting center in the brain. • Tumor location • Radiation therapy • Anticipatory nausea

  32. Interventions • Antiemetics such as Phenothiazines: (Trilafon), (Phenergan)and (Thorazine) block dopamine receptors from stimulating the chemoreceptor trigger zones. • Serotonin-receptor antagonist such as Granisetron (Kytril) and Ondansetron (Zofran) are very effective. (>3 years) • Antihistamines: benadryl • Administer before chemotherapy

  33. Mucositis • Progressive, inflammatory, ulcerative condition of the oral and gastric mucosa. • Occurs due to the interruption of cell renewal process of the epithelium leading the mucosal atrophy and ulceration • Thrombocytopenia or physical trauma may lead to bleeding and further mucosal damage. • Neutropenia and poor dental hygiene predisposes the oral mucosa to secondary infection.

  34. Assessment / Interventions • Baseline assessment including the oral cavity, teeth, and gingival mucosa. • History of dental exam and use of orthodontic appliances • Meticulous oral care • Mouth rinses • Monitor hydration status

  35. Constipation • Assess normal bowel habits • Increase fiber and fluids in diet • Stool softeners / colace • Physical activity • Avoid digital manipulation

  36. Diarrhea • Assess for signs of dehydration • Record stool patterns • IV fluids as needed • Low-residue or lactose-free diet • Good hand washing

  37. Hair Loss • More important in the older child. • Most patients will experience hair loss within 10 days of induction chemotherapy • Prepare patient for hair loss • Males: shave hair • Females: short hair style – pick out wig – scarf - hat

  38. Psychosocial Support • Support groups • Open communication • Daily contact with oncology team • Trusting relationship with nurse

  39. Growth and Development • Promote normal G & D • Allow decision making • Establish daily routines • Play therapy • Friends • School attendance or tutor

  40. Late Effects of Cancer Therapy • Endocrine: sterility • Thyroid • Cardiovascular • Musculoskeletal • Vision • Hearing • Respiratory • Gastrointestinal • Genitourinary • Hematopoietic

  41. Leukemia • Most common malignancy • Cancer of blood or bone marrow characterized by an abnormal proliferation of blood cells, usually white blood cells (leukocytes) • Two types • Acute lymphoblastic leukemia: 78% • Acute Myelogenous leukemia: 15 to 20% • High survival rate

  42. Prognosis • Initial WBC most significant • The higher the count the poorer the outcomes • Greater than 100,000 WBC count = poor outcome • Children under 2 years and older than 10 • Girls do better than boys

  43. Diagnosis • Peripheral blood smear • Bone marrow analysis • Lumbar puncture

  44. Assessment • Pallor and fever • Lethargy • Anorexia • Weight loss • Hemorrhage / petechiae • Hepatomegly / splenomegaly

  45. 3 Phase Treatment • Induction: goal is to achieve remission last about a month • Consolidation: most intensive phase of chemotherapy lasts 4 to 8 months • Maintenance: last two to three years • If leukemia cells are detected in bone marrow process is started all over again.

  46. Induction Therapy • Goal of therapy is to achieve remission • Leukemia cells are no longer found in the bone marrow samples, the normal cells return and blood counts become normal. • Drugs used: L-asparaginase, vincristine and a steroid (dexamethasone), for high-risk children a fourth drug (daunorbucin) is often used

  47. Consolidation Phase • Several drugs are used in combination to prevent remaining leukemia cells from developing resistance. • Drugs include: methotrexate and 6-mercaptopurine, vincristine and prednisone

  48. Maintenance • If leukemia continues to be in remission maintenance therapy can be started. • Two drugs: vincristine and steroids over a brief period every 4 to 8 weeks. • Duration of total therapy 2 to 3 years.

  49. CNS Therapy • CNS prophylaxis is initiated at diagnosis and is used to reduce the risk for CNS disease. • Preventive CNS is based on the premise that the CNS provides a sanctuary site for leukemic cells that are undetected at diagnosis and reside protected from the action of systemic therapy by the brain blood barrier.

  50. Multidisciplinary Interventions • Assess for infection • Monitor blood values • I & O / nutrition • Complications of chemotherapy • Good hand washing • Aseptic technique for blood draws

More Related